Cash and cash equivalents were $5.2 million as of September 30, 2024, compared to $2.8 million as of December 31, 2023. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the second half of 2025 based on currently committed development plans.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADIL:
- Adial Pharmaceuticals Approves Strategic Changes at Annual Meeting
- Adial Pharmaceuticals Appoints New Chief Financial Officer
- Adial Pharmaceuticals appoints Shah as Chief Financial Officer
- Adial receives notice of allowance for U.S. patent related to AD04
- Adial Pharmaceuticals commends NIAAA’s new definition of recovery